{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:40:14Z","timestamp":1784011214160,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225724\/Z\/22\/Z"],"award-info":[{"award-number":["225724\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["2021\/GNT2007839"],"award-info":[{"award-number":["2021\/GNT2007839"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejca.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:17:13Z","timestamp":1683548233000},"page":"112914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Adjuvant therapy for stage II melanoma: the need for further studies"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-2009","authenticated-orcid":false,"given":"Rebecca","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-8959","authenticated-orcid":false,"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-2164","authenticated-orcid":false,"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejca.2023.05.003_bib1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2023.05.003_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.05.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"issue":"19","key":"10.1016\/j.ejca.2023.05.003_bib4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2023.05.003_bib5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2023.05.003_bib6","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2023.05.003_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant Dabrafenib plus Trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2023.05.003_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl_7","key":"10.1016\/j.ejca.2023.05.003_bib9","first-page":"S808","article-title":"Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: long-term quality of life analysis results of the EORTC 1325 [Internet]","volume":"33","author":"Bottomley","year":"2022","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2023.05.003_bib10","doi-asserted-by":"crossref","first-page":"9574","DOI":"10.1200\/JCO.2021.39.15_suppl.9574","article-title":"Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB\/C or IV melanoma: analysis of CheckMate 238 four-year follow-up (FU) data","volume":"39","author":"Weber","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.ejca.2023.05.003_bib11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1470-2045(18)30940-9","article-title":"Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Schadendorf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.05.003_bib12","first-page":"177","article-title":"Checkmate 238: 5-year follow-up of nivolumab in the adjuvant treatment of melanoma","volume":"35","author":"Weber","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.003_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.05.003_bib14","doi-asserted-by":"crossref","unstructured":"Long GV, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: overall survival and response rates from RELATIVITY-047 (CA224-047). 2022;40(36_suppl):360385\u2013360385. https:\/\/doi.org\/101200\/JCO20224036_suppl360385.","DOI":"10.1200\/JCO.2022.40.36_suppl.360385"},{"key":"10.1016\/j.ejca.2023.05.003_bib15","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall survival and response with Nivolumab and Relatlimab in advanced melanoma","author":"Long","year":"2023","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.003_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer\u2606","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"issue":"8_Supplement","key":"10.1016\/j.ejca.2023.05.003_bib17","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT002","article-title":"Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma","volume":"83","author":"Dummer","year":"2023","journal-title":"Cancer Res"},{"issue":"8_Supplement","key":"10.1016\/j.ejca.2023.05.003_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT001","article-title":"CT001 - a personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201\/Keynote-942 trial","volume":"83","author":"Khattak","year":"2023","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.003_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ejca.2023.05.003_bib20","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.05.003_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.039","article-title":"LBA6 neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.05.003_bib22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.05.003_bib23","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.05.003_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605","article-title":"The NADINA trial: a multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma","volume":"40","author":"Lucas","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"7934","key":"10.1016\/j.ejca.2023.05.003_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2023.05.003_bib26","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"10.1016\/j.ejca.2023.05.003_bib27","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.19.03034","article-title":"Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.05.003_bib28","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.05.003_bib29","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (\u2a7d1\u202fmm) than from thick melanomas (4\u202fmm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Investig Dermatol"},{"issue":"10336","key":"10.1016\/j.ejca.2023.05.003_bib30","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.ejca.2023.05.003_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2022.08.004","article-title":"Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: health-related quality of life from the randomized phase 3 KEYNOTE-716 study","volume":"176","author":"Khattak","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.003_bib32","first-page":"1","article-title":"Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB\/C melanoma (CheckMate 76K)","volume":"35","author":"Long","year":"2022","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2023.05.003_bib33","first-page":"1","article-title":"Decision-making and health-related quality of life in patients with melanoma considering adjuvant immunotherapy","author":"Atkinson","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2023.05.003_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.05.003_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell\u2013driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC Cardio Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-022-00149-8","article-title":"Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study","volume":"8","author":"Wang","year":"2022","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.ejca.2023.05.003_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102280","article-title":"Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: a systematic review and meta-analysis","volume":"100","author":"Giustozzi","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ejca.2023.05.003_bib38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2023.05.003_bib39","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab Plus Ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2023.05.003_bib40","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1002\/cncr.32984","article-title":"Outcomes after progression of disease with anti-PD-1\/PDL1 therapy for advanced melanoma","volume":"126","author":"Patrinely","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.05.003_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2021.09.023","article-title":"Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG\/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma","volume":"158","author":"Eggermont","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.05.003_bib42","unstructured":"Atkins\u200b\u00a0\u200b\u200bMB\u200b,\u00a0\u200b\u200b\u200bLee\u200b\u00a0\u200b\u200bSJ\u200b,\u00a0\u200b\u200b\u200bChmielowski\u200b\u00a0\u200b\u200bB\u200b,\u00a0\u200b\u200b\u200bTarhini\u200b\u00a0\u200b\u200bAA\u200b,\u00a0\u200b\u200b\u200bCohen\u200b\u00a0\u200b\u200bGI,\u00a0\u200b\u200b\u200bTruong\u200b\u00a0\u200b\u200bT-G\u200b,\u00a0\u200b\u200bet al.\u200b\u00a0\u200b\u200bCombination Dabrafenib and Trametinib versus combination Nivolumab and Ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134\u200b.\u00a0\u200b\u200bJ Clin Oncol\u200b."},{"issue":"2","key":"10.1016\/j.ejca.2023.05.003_bib43","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated\u00a0BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.05.003_bib44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.05.003_bib45","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","article-title":"Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma","volume":"2","author":"Haas","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2023.05.003_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","article-title":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","volume":"125","author":"Amaral","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.05.003_bib47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.021","article-title":"Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)","volume":"182","author":"Amaral","year":"2023","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2023.05.003_bib48","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/cancers14122854","article-title":"Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I\u2013II melanoma patients at risk of disease relapse","volume":"14","author":"Mulder","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.003_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","article-title":"Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria","volume":"80","author":"Gastman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.003_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21207-2","article-title":"Tumour gene expression signature in primary melanoma predicts long-term outcomes","volume":"12","author":"Garg","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.003_bib51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2023.05.003_bib52","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.05.003_bib53","first-page":"1","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"16","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"issue":"7867","key":"10.1016\/j.ejca.2023.05.003_bib54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2023.05.003_bib55","first-page":"1","article-title":"Circulating tumour DNA in melanoma\u2014clinic ready?","volume":"1","author":"Tivey","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.003_bib56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.05.003_bib57","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.05.003_bib58","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdz075","article-title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:05Z","timestamp":1760733725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":58,"alternative-id":["S095980492300240X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.05.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant therapy for stage II melanoma: the need for further studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112914"}}